Article
Oncology
Alan P. Venook, Christopher G. Willett
Summary: Advances in the treatment of advanced colorectal cancer have been slow in recent years, with a focus on finding new approaches beyond traditional methods. Locally advanced colorectal cancer patients are achieving good long-term outcomes with contemporary treatment strategies, and total neoadjuvant therapy has shown significant improvements in the treatment of rectal cancer patients.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Review
Oncology
Jemmy Zhao, Susann Stephan-Falkenau, Markus Schuler, Boerge Arndt
Summary: This review discusses the recent advances in genetic and molecular characterization of combined hepatocellular-cholangiocarcinoma (cHCC-CC), a rare and aggressive liver tumor with features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). The optimal treatment for cHCC-CC has not been defined due to its rarity, but liver resection is the mainstay treatment for resectable disease. For advanced disease, there is a lack of guideline recommendations or prospective trial reports to evaluate treatment options. This review explores locoregional and medical treatment approaches for advanced cHCC-CC and discusses the potential of predictive biomarker-guided therapies.
Article
Oncology
Elaine Chang, Chana Weinstock, Lijun Zhang, Rosane Charlab, Sarah E. Dorff, Yutao Gong, Vicky Hsu, Fang Li, Tiffany K. Ricks, Pengfei Song, Shenghui Tang, Peter E. Waldron, Jingyu Yu, Eias Zahalka, Kirsten B. Goldberg, Richard Pazdur, Marc R. Theoret, Amna Ibrahim, Julia A. Beaver
Summary: Enfortumab vedotin-ejfv has been granted accelerated approval by the FDA for the treatment of locally advanced or metastatic urothelial cancer. The drug showed certain efficacy in clinical trials but also comes with a high rate of adverse reactions. This approval is subject to further verification and description of clinical benefits in confirmatory trials.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Mrinal M. Gounder, Priscilla Merriam, Ravin Ratan, Shreyaskumar R. Patel, Rashmi Chugh, Victor M. Villalobos, Mark Thornton, Brian A. Van Tine, Amr H. Abdelhamid, Jennifer Whalen, Jay Yang, Anand Rajarethinam, Mei Sheng Duh, Priyanka J. Bobbili, Lynn Huynh, Todor Totev, Angela K. Lax, Shefali Agarwal, George D. Demetri
Summary: For patients with advanced epithelioid sarcoma (ES) who have received two or more lines of systemic therapy, the overall response rate is less than 15%, the disease control rate is 20%, the median duration of response is 4.5 months, and the median progression-free survival is 6.0 months. Serious adverse events include febrile neutropenia, pain, and anemia.
Review
Oncology
Anabela G. Barros, Catarina F. Pulido, Manuela Machado, Maria Jose Brito, Nuno Couto, Olga Sousa, Sonia A. Melo, Helder Mansinho
Summary: PDAC is a deadly malignant tumor with limited treatment options. Surgery is the only curative treatment, but many patients are diagnosed at a late stage. A multidisciplinary approach and molecular research are promising for future treatments.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2021)
Article
Oncology
Alice Baggi, Pietro Quaglino, Marco Rubatto, Roberta Depenni, Michele Guida, Paolo Antonio Ascierto, Claudia Trojaniello, Paola Queirolo, Maristella Saponara, Ketty Peris, Francesco Spagnolo, Luca Bianchi, Federica De Galitiis, Maria Concetta Potenza, Ilaria Proietti, Riccardo Marconcini, Andrea Botticelli, Vito Barbieri, Lisa Licitra, Salvatore Alfieri, Corrado Ficorella, Alessio Cortellini, Maria Concetta Fargnoli, Teresa Troiani, Luca Tondulli, Paolo Bossi
Summary: A retrospective observational study in Italy evaluated the clinical outcomes of patients with advanced cSCC treated with cemiplimab. The study showed comparable safety and effectiveness results to clinical trials, and identified some clinical and biochemical factors potentially associated with response to cemiplimab.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Lucie Meynard, Derek Dinart, Blandine Delaunay, Aude Flechon, Carolina Saldana, Felix Lefort, Gwenaelle Gravis, Antoine Thiery-Vuillemin, Mathilde Cancel, Elodie Coquan, Sylvain Ladoire, Denis Maillet, Frederic Rolland, Elouen Boughalem, Sophie Martin, Mathieu Laramas, Laurence Crouzet, Baptiste Abbar, Sabrina Falkowski, Damien Pouessel, Guilhem Roubaud
Summary: This study assessed the efficacy of chemotherapy re-challenge after immune checkpoint inhibitors (ICIs) in patients with locally advanced or metastatic urothelial carcinoma and compared it with second-line chemotherapy without previous ICIs. The results showed that chemotherapy re-challenge after ICIs achieved similar objective response rates and progression-free survival as second-line chemotherapy without previous ICIs, with an acceptable safety profile.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Medicine, General & Internal
Amelia M. Taylor, David Lok Hang Chan, Martin Tio, Sujata M. Patil, Tiffany A. Traina, Mark E. Robson, Mustafa Khasraw
Summary: PARP inhibitors show potential benefits in improving survival and tumor response rates in patients with locally advanced or metastatic HER2-negative, BRCA germline mutated breast cancer. More research is needed to further explore the impact of PARP inhibitors on quality of life outcomes and their role in other relevant breast cancer populations.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Article
Oncology
Cora N. Sternberg, Ian D. Davis, Jozef Mardiak, Cezary Szczylik, Eunsik Lee, John Wagstaff, Carlos H. Barrios, Pamela Salman, Oleg A. Gladkov, Alexander Kavina, Juan J. Zarba, Mei Chen, Lauren McCann, Lini Pandite, Debasish F. Roychowdhury, Robert E. Hawkins
Summary: This study evaluated the efficacy and safety of Pazopanib in the treatment of advanced renal cell carcinoma. The results showed significant improvement in progression-free survival and tumor response with Pazopanib compared to placebo.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Dapeng Li, Yihebali Chi, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan Cheng, Zhengang Xu, Xiangqian Zheng, Pingzhang Tang, Ming Gao
Summary: Anlotinib demonstrated significant improvement in progression-free survival and objective response rate in patients with MTC, with a higher incidence of treatment-related adverse events. However, it showed relatively reliable safety profile in this population.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Francesca Jackson-Spence, Bernadett Szabados, Charlotte Toms, Yu-Hsuen Yang, Christopher Sng, Thomas Powles
Summary: Outcomes for patients with advanced or metastatic urothelial carcinoma (UC) are poor, but targeting the PD-L1 immune checkpoint pathway with a PD-L1 inhibitor like avelumab has shown promise. Avelumab restores cytotoxic and antitumor T cell response in UC patients. Maintenance treatment with avelumab following platinum-based chemotherapy has become the new standard of care for advanced or metastatic UC.
EXPERT REVIEW OF ANTICANCER THERAPY
(2022)
Article
Oncology
Yueyun Ma, Wenjie Li, Shiyu Chen, Shuimiao Lin, Sijie Ding, Xiaomei Zhou, Tongxin Liu, Rong Wang, Wei Wang
Summary: In this study, a comprehensive analysis was performed on patients with advanced or metastatic esophageal cancer who underwent next-generation sequencing (NGS). Mutations in 227 genes were identified, with TP53, NQO1, DPYD, GSTM1, XRCC1 and ERCC1 being the most common. Patients who received NGS-guided therapy showed improved clinical outcomes. The study highlights the importance of NGS in precision therapy for esophageal cancer.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Hossein Taghizadeh, Angela Djanani, Wolfgang Eisterer, Armin Gerger, Birgit Gruenberger, Thomas Gruenberger, Holger Rumpold, Lukas Weiss, Thomas Winder, Ewald Woell, Gerald W. Prager
Summary: Locally advanced or metastatic cholangiocarcinoma is a difficult-to-treat cancer with few options. Cisplatin/gemcitabine has been the standard first-line treatment for over 10 years, but the addition of the immune checkpoint inhibitor durvalumab has shown improved efficacy in phase III trials. Second-line chemotherapy has limited evidence, with FOLFOX being the only positive phase III option. Targeted therapies can be considered after first-line treatment failure, targeting specific molecular markers such as MSI-H, IDH1, FGFR2, BRAF V600E, and NTRK. Broad molecular testing at the start of treatment is recommended to identify potential targets.
FRONTIERS IN ONCOLOGY
(2023)
Review
Biotechnology & Applied Microbiology
Jean Hoffman-Censits, Laneisha Maldonado
Summary: Enfortumab vedotin (EV) is a novel antibody-drug conjugate that has been FDA-approved for the treatment of treatment-refractory urothelial cancer. It has shown high activity in patients with poor prognosis, and has a good tolerability profile. Ongoing trials are exploring its use in different disease states and in combination with other agents.
ONCOTARGETS AND THERAPY
(2022)
Article
Oncology
Gino Kim In, Aparna Nallagangula, Jacob Seung Choi, Lisa Tachiki, Matthew J. Blackburn, Stephen Capone, Kathryn B. Bollin, Daniel Y. Reuben, Keisuke Shirai, Sandy Zhang-Nunes, Omar Ragab, Alicia Terando, Jenny C. Hu, Han Lee, Shailender Bhatia, Sunandana Chandra, Jose Lutzky, Geoffrey Thomas Gibney
Summary: This study conducted a multicenter, retrospective analysis of BCC patients treated with PD-1 inhibitor therapy, demonstrating good efficacy and safety. Some patients achieved partial or complete responses with PD-1 inhibition.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Gastroenterology & Hepatology
Li Chen, Moli Huang, Jasmine Plummer, Jian Pan, Yan Yi Jiang, Qian Yang, Tiago Chedraoui Silva, Nicole Gull, Stephanie Chen, Ling Wen Ding, Omer An, Henry Yang, Yulan Cheng, Jonathan W. Said, Ngan Doan, Winand N. M. Dinjens, Kevin M. Waters, Richard Tuli, Simon A. Gayther, Samuel J. Klempner, Benjamin P. Berman, Stephen J. Meltzer, De-Chen Lin, H. Phillip Koeffler
Article
Gastroenterology & Hepatology
Amr I. Al Abbas, Jeffrey D. Borrebach, Johanna Bellon, Amer H. Zureikat
JOURNAL OF GASTROINTESTINAL SURGERY
(2020)
Article
Gastroenterology & Hepatology
Aatur D. Singhi, Laura D. Wood, Emma Parks, Michael S. Torbenson, Matthaus Felsenstein, Ralph H. Hruban, Marina N. Nikiforova, Abigail I. Wald, Cihan Kaya, Yuri E. Nikiforov, Laura Favazza, Jin He, Kevin McGrath, Kenneth E. Fasanella, Randall E. Brand, Anne Marie Lennon, Alessandro Furlan, Anil K. Dasyam, Amer H. Zureikat, Herbert J. Zeh, Kenneth Lee, David L. Bartlett, Adam Slivka
Review
Oncology
Samuel J. Klempner, David Fabrizio, Shalmali Bane, Marcia Reinhart, Tim Peoples, Siraj M. Ali, Ethan S. Sokol, Garrett Frampton, Alexa B. Schrock, Rachel Anhorn, Prasanth Reddy
Article
Surgery
Amer H. Zureikat, Joal D. Beane, Mazen S. Zenati, Amr Al Abbas, Brian A. Boone, A. James Moser, David L. Bartlett, Melissa E. Hogg, Herbert J. I. I. I. I. I. I. Zeh
Summary: This study presents outcomes of robotic pancreatoduodenectomy over a decade, showing improvements in operative time, blood loss, and postoperative complications with increasing experience. Structured implementation of robotic pancreatoduodenectomy can lead to excellent outcomes, establishing benchmarks for the surgical community to consider when adopting this approach.
Editorial Material
Oncology
Samuel J. Klempner, Aaron N. Hata
Editorial Material
Oncology
Samuel J. Klempner, Vivek Upadhyay, Joseph Chao
CLINICAL CANCER RESEARCH
(2020)
Article
Oncology
Arturo Loaiza-Bonilla, Al B. Benson, Axel Grothey, Misagh Karimi, Samuel J. Klempner, Daniel Lin, Reshma Mahtani, Heloisa P. Soares
Summary: Genomic testing is becoming crucial in cancer diagnosis and treatment decision-making, especially in gastrointestinal cancers like colorectal cancer. Advancements in technology allow for noninvasive screening for CRC through blood or stool tests, while also providing prognostic information and guiding therapy selection.
Article
Oncology
Minsuk Kwon, Minae An, Samuel J. Klempner, Hyuk Lee, Kyoung-Mee Kim, Jason K. Sa, Hee Jin Cho, Jung Yong Hong, Taehyang Lee, Yang Won Min, Tae Jun Kim, Byung-Hoon Min, Woong-Yang Park, Won Ki Kang, Kyu-Tae Kim, Seung Tae Kim, Jeeyun Lee
Summary: The study shows that patients with microsatellite instability and elevated mutational burden in gastric cancer are associated with clinical response to anti-PD-1 antibodies. By combining whole-exome sequencing with single-cell RNA sequencing, dynamic tumor evolution with collapse of mutational architecture in responders is identified. Diversity in T-cell receptor repertoire is linked to better response to pembrolizumab.
Article
Oncology
David A. Drew, Samuel J. Klempner, Andrew T. Chan
Summary: Early detection and interception of gastric cancer globally is limited, especially for individuals without established hereditary risk factors. Establishing biomarkers using multiple-omic approaches may be crucial for identifying individuals at risk and for more intensive evaluation. Multifactorial risk assessment is needed for precision prevention and early detection of gastric cancer.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2021)
Article
Oncology
Jennifer Y. Wo, Jeffrey W. Clark, Christine E. Eyler, Mari Mino-Kenudson, Samuel J. Klempner, Jill N. Allen, Florence K. Keane, Aparna R. Parikh, Eric Roeland, Lorraine C. Drapek, David P. Ryan, Ryan B. Corcoran, Emily Van Seventer, Isobel J. Fetter, Heather A. Shahzade, Melin J. Khandekar, Michael Lanuti, Christopher R. Morse, Rebecca S. Heist, Christine A. Ulysse, Benjamin Christopher, Christian Baglini, Beow Y. Yeap, John T. Mullen, Theodore S. Hong
Summary: The study demonstrated the feasibility of neoadjuvant FOLFIRINOX followed by chemoradiation for locally advanced gastric or gastroesophageal cancer, with a high rate of pathologic complete response. ctDNA shows promise as a predictor for postoperative recurrence.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Jasmine Huynh, Kanishka Patel, Jun Gong, May Cho, Midhun Malla, Aparna Parikh, Samuel Klempner
Summary: Immunotherapy in the treatment of gastroesophageal cancer is evolving and showing promising results, especially with adjuvant immunotherapy and combination therapies. However, challenges remain in treating PD-L1 negative subgroups, indicating the need for further research in biologic understanding and effective therapies. Combination angiogenesis inhibitors and immunotherapy show potential, but more studies are required to optimize treatment strategies.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2021)
Article
Oncology
Samuel J. Klempner, Johanna C. Bendell, Victoria Meucci Villaflor, Laura LaNiel Tenner, Stacey M. Stein, James B. Rottman, Girish S. Naik, Cynthia A. Sirard, Michael H. Kagey, Marya F. Chaney, John H. Strickler
Summary: The study evaluated the safety and efficacy of combination therapy with DKN-01 and pembrolizumab in patients with advanced esophago-gastric cancer, finding better therapeutic outcomes in patients with high DKK1 expression, independent of PD-L1 expression.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Oncology
Adi Diab, Omid Hamid, John A. Thompson, Willeke Ros, Ferry A. L. M. Eskens, Toshihiko Doi, Siwen Hu-Lieskovan, Samuel J. Klempner, Bishu Ganguly, Catherine Fleener, Xiao Wang, Tenshang Joh, Ken Liao, Shahram Salek-Ardakani, Carrie Turich Taylor, Jeffrey Chou, Anthony B. El-Khoueiry
Summary: This study investigates the potential of Ivuxolimab in the treatment of cancer. The results demonstrate that Ivuxolimab is well tolerated and safe, and shows anti-tumor activity. Additionally, this study also finds that Ivuxolimab can activate the immune system, enhancing T-cell activation and proliferation, and has a certain control effect on tumors.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Andrew Hendifar, Edik M. Blais, Brian Wolpin, Vivek Subbiah, Eric Collisson, Isha Singh, Timothy Cannon, Kenna Shaw, Emanuel F. Petricoin, Samuel Klempner, Emily Lyons, Andrea Wang-Gillam, Michael J. Pishvaian, Eileen M. O'Reilly
Summary: In pancreatic cancer patients with RAF family alterations, different mutational subgroups were identified and their clinical characteristics were determined, which may contribute to the development of future treatment strategies.
JCO PRECISION ONCOLOGY
(2021)